CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 211 enrolled
Drug / intervention
Atomoxetinedrug
Likely dose
Atomoxetine 120 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00969618
NCT00969618Phase 3Completed
CompareCT.gov

Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)

Eli Lilly and Company·interventional·Posted Sep 1, 2009·Updated Dec 12, 2012

In Brief

A Phase 3 clinical trial evaluating Atomoxetine for Attention Deficit Hyperactivity Disorder. Completed, enrolled 211 participants across 12 sites.

Detailed Summary

The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 1, 2009
Enrollment StartNov 1, 2009
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.8 years ago

Interventions

Atomoxetinedrug

40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks